MDS Clinical Trials

MDS clinical trials are the most effective way to evaluate new treatments for myelodysplastic syndromes. Most trials are designed to compare an emerging therapy to a treatment that is already recommended for MDS patients. This helps researchers determine if the new treatment is more effective than the current standard of care, and also whether one treatment causes fewer side effects than the other.

Moffitt Cancer Center hosts a wide range of MDS clinical trials on a regular basis. As a member of the Bone Marrow Failure Disease Consortium – a collaborative research group dedicated to the study of myelodysplastic syndromes and similar diseases – Moffitt has received many coveted research grants from the National Institutes of Health. As a result, our team has had the ability to investigate:

  • Novel chemotherapy agents and combinations of multiple agents
  • Supportive care options, such as online and social media-based support groups for transplant recipients
  • Targeted medications that have the potential to reduce the likelihood of recurrence after MDS treatment

Through our MDS clinical trials, Moffitt has given countless patients a way to benefit from innovative treatments that aren’t yet available in other settings. In some cases, these treatments opened new doors for patients who didn’t respond to traditional therapies; in other cases, these treatments provided hope to patients who were not eligible for bone marrow transplants. While no patient is ever required to participate in a clinical trial, our malignant hematologists can help match interested individuals with trials that meet their specific needs.

To learn more about MDS clinical trials at Moffitt, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Referrals are not required.

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 19635

A Phase 1b/2 Study Evaluating the Safety and Efficacy of Intravenous LB-100 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) who had Disease Progression or are Intolerant to Prior Therapy

Disease Site: Leukemia, other, Myelodysplastic syndrome (MDS)

View Trial Details

CLINICAL TRIAL 19658

A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy

Disease Site: Myelodysplastic syndrome (MDS), Leukemia, other

View Trial Details

CLINICAL TRIAL 19862

A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

Disease Site: Acute Leukemia (ALL, AML), Myelodysplastic syndrome (MDS), Myeloid and Monocytic Leukemia

View Trial Details

CLINICAL TRIAL 20042

CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients with MDS and Secondary AML

Disease Site: Acute Leukemia (ALL, AML), Myelodysplastic syndrome (MDS), Myeloid and Monocytic Leukemia

View Trial Details